Valiant Laboratories Ltd. (IN:VALIANTLAB)
:VALIANTLAB
Want to see IN:VALIANTLAB full AI Analyst Report?
Top Page
Valiant Laboratories Ltd.
(VALIANTLAB)
Select Model
Select Model
Rating:54Neutral
Price Target:
₹80.00
▲(8.84% Upside)
Action:Reiterated
Date:05/18/26
The score is held back primarily by weak financial quality—losses, near break-even operating profitability, and negative operating/free cash flow—despite a healthier balance sheet and a notable FY2026 revenue rebound. Technicals are supportive with the stock trading above key moving averages and positive MACD momentum, but valuation remains constrained because the company is currently unprofitable and offers no dividend yield data.
Positive Factors
Modest leverage and sizable equity base
A large equity base versus modest debt provides structural financial flexibility: it supports ongoing operations, helps absorb cyclical API demand, and reduces near-term refinancing risk. This enduring balance-sheet strength can fund selective investment or cushion downturns without heavy leverage.
Negative Factors
Weak operating and free cash flow
Sustained negative operating and free cash flow forces reliance on external funding for working capital and investments, constrains reinvestment and reduces optionality. Persistent cash burn raises execution risk and limits the company's ability to self-fund growth or return capital to shareholders over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Modest leverage and sizable equity base
A large equity base versus modest debt provides structural financial flexibility: it supports ongoing operations, helps absorb cyclical API demand, and reduces near-term refinancing risk. This enduring balance-sheet strength can fund selective investment or cushion downturns without heavy leverage.
Read all positive factors
Valiant Laboratories Ltd. (VALIANTLAB) vs. iShares MSCI India ETF (INDA)
Market Cap
₹4.04B
Dividend YieldN/A
Average Volume (3M)1.58K
Price to Earnings (P/E)―
Beta (1Y)0.78
Revenue Growth78.04%
EPS Growth-16.99%
CountryIN
Employees77
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)1.13
Shares Outstanding54,312,500
10 Day Avg. Volume2,243
30 Day Avg. Volume1,577
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)1.06
Price to Sales (P/S)1.39
P/FCF Ratio-6.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Valiant Laboratories Ltd. Business Overview & Revenue Model
Company Description
Valiant Laboratories Limited operates as an active pharmaceutical ingredient/bulk drug manufacturing company in India and internationally. The company manufactures paracetamol in various grades, such as Indian/British/European/the United States ph...
How the Company Makes Money
Valiant Laboratories Ltd. primarily makes money by manufacturing and selling APIs (and related pharmaceutical inputs) to business customers such as pharmaceutical formulators and finished-dosage manufacturers. Revenue is generated from product sal...
Valiant Laboratories Ltd. Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
71
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.84B | 2.37B | 1.39B | 1.82B | 3.34B | 2.92B |
| Gross Profit | 267.32M | 272.66M | 222.17M | 115.76M | 565.90M | 523.21M |
| EBITDA | 92.87M | 63.90M | 7.55M | -85.98M | 399.53M | 442.67M |
| Net Income | 50.70M | -32.68M | -22.01M | 3.20M | 289.98M | 274.96M |
Balance Sheet | ||||||
| Total Assets | 4.25B | 4.64B | 4.01B | 3.43B | 2.13B | 1.82B |
| Cash, Cash Equivalents and Short-Term Investments | 629.06M | 331.50M | 759.91M | 1.44B | 353.61M | 205.33M |
| Total Debt | 537.68M | 462.12M | 1.22B | 767.08M | 602.17M | 611.26M |
| Total Liabilities | 1.07B | 1.53B | 1.67B | 1.06B | 1.12B | 1.10B |
| Stockholders Equity | 3.17B | 3.11B | 2.34B | 2.37B | 1.00B | 714.60M |
Cash Flow | ||||||
| Free Cash Flow | -1.39B | -471.97M | -1.13B | -439.85M | 183.70M | -46.25M |
| Operating Cash Flow | -57.24M | -129.97M | 13.13M | 18.85M | 560.51M | 22.51M |
| Investing Cash Flow | -604.96M | 72.52M | -527.68M | -1.44B | -551.68M | -122.38M |
| Financing Cash Flow | 576.22M | 43.57M | 446.53M | 1.52B | -9.34M | 61.81M |
Valiant Laboratories Ltd. Technical Analysis
Neutral
73.50
Price Trends
65.94
Positive
64.65
Positive
73.23
Positive
Market Momentum
2.72
Positive
53.39
Neutral
6.27
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VALIANTLAB, the sentiment is Neutral. The current price of 73.5 is below the 20-day moving average (MA) of 78.11, above the 50-day MA of 65.94, and above the 200-day MA of 73.23, indicating a neutral trend. The MACD of 2.72 indicates Positive momentum. The RSI at 53.39 is Neutral, neither overbought nor oversold. The STOCH value of 6.27 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:VALIANTLAB.
Valiant Laboratories Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | ₹1.44B | 21.48 | ― | ― | 18.92% | -53.80% | |
56 Neutral | ₹515.88M | 172.45 | ― | ― | -27.51% | 356.89% | |
54 Neutral | ₹4.04B | -100.74 | ― | ― | 78.04% | -16.99% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | ₹396.80M | -4.63 | ― | ― | -48.93% | -180.45% | |
45 Neutral | ₹1.19B | -11.90 | ― | ― | -53.19% | 6.75% | |
39 Underperform | ₹543.09M | -2.21 | ― | ― | -35.33% | -65.64% |
* Healthcare Sector Average
IN:VALIANTLAB
Valiant Laboratories Ltd.
75.80
-21.63
-22.20%
IN:ALPA
Alpa Laboratories Limited
69.84
-37.11
-34.70%
IN:BIOFILCHEM
Biofil Chemicals & Pharmaceuticals Ltd.
31.45
-14.09
-30.94%
IN:KREBSBIO
Krebs Biochemicals & Industries Ltd.
53.81
-19.48
-26.58%
IN:LASA
Lasa Supergenerics Ltd.
8.06
-9.01
-52.78%
IN:VIVIMEDLAB
Vivimed Labs Limited
6.60
1.70
34.69%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.